Get the Stockscreener App
1.59
4.61%
0.07
After Hours:
1.59
Aldeyra Therapeutics Inc stock is traded at $1.59, with a volume of 743.75K.
It is up +4.61% in the last 24 hours and down -5.36% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.52
Open:
$1.52
24h Volume:
743.75K
Relative Volume:
0.26
Market Cap:
$95.91M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.8201
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
+2.58%
1M Performance:
-5.36%
6M Performance:
-68.64%
1Y Performance:
-41.33%
1-Day Range:
$1.5088
$1.60
1-Week Range:
$1.47
$1.62
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.59 | 95.91M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Malone Telegram
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Aldeyra Updates Reproxalap Outlook and Extends Cash Runway - TipRanks
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Lebanon Democrat
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
AbbVie option and FDA feedback reshape Aldeyra (Nasdaq: ALDX) drug plans - Stock Titan
MSN Money - MSN
Press releases provided by CNW - Techaeris
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - ChartMill
REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - ChartMill
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GuruFocus
ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - Morningstar
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Executives Allegedly Certified Misleading Filings: SueWallSt - Morningstar
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Does Aldeyra Therapeutics (ALDX) have the potential to rally 79.28% as Wall Street analysts expect? - MSN
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc. - The Joplin Globe
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Aldeyra Therap - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - ChartMill
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - marketscreener.com
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - ChartMill
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
Aldeyra Therapeutics | DEF 14A: Definitive information statements - Moomoo
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire
[ARS] Aldeyra Therapeutics, Inc. SEC Filing - Stock Titan
CEO pay, board election and auditor up for Aldeyra (NASDAQ: ALDX) 2026 vote - Stock Titan
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra - GlobeNewswire
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ALDX Technical Analysis | Trend, Signals & Chart Patterns | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - marketscreener.com
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to ... - Bluefield Daily Telegraph
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Coty Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – COTY - GlobeNewswire Inc.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Encourages Aldeyra - GlobeNewswire
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. ... - Bluefield Daily Telegraph
ALDX Forecast, Price Target & Analyst Ratings | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX (Aldeyra Therapeutics Inc.) reports narrower Q4 2025 loss than forecast, topping consensus EPS estimates by 60 percent.Decline Phase - Xã Thanh Hà
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have - The National Law Review
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
| Alfieri Michael | Principal Financial Officer |
Aug 13 '25 |
Buy |
5.30 |
2,500 |
13,250 |
2,500 |
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):